Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

•A tetravalent dengue vaccine (TDV) was evaluated in a Phase 1b clinical trial.•The different dose schedules and formulations of TDV were well tolerated.•Greater that 80% of subjects seroconverted to three or more dengue viruses.•Dosing twice on one day or reducing the dose had little effect on immunogenicity.•These dose ranging studies help inform future Phase 2 and Phase 3 trials of TDV.